The deal is initially aimed at using the companies’ complementary scientific platforms within the framework of ongoing research projects.
Both the firms will assess results achieved to date, then explore the potential for a closer collaboration focusing on bringing products to market in a time-efficient manner.
Costs related to the deal will be covered by each firm separately and within budgeted development projects.
The two firms will retain exclusive ownership rights to existing registered intellectual property.
NeuroVive CEO Mikael Brönnegård said the company is happy to collaborate with A1M Pharma, which will give both parties access to a broader scientific platform in mitochondrial medicine.
"The companies’ adjacent research areas and strong R&D backgrounds, combined with their geographical proximity, will secure a smooth integration of existing research projects," Brönnegård said.
A1M Pharma CEO Tomas Eriksson said the collaboration will improve the potential for both parties to conduct leading research in mitochondrial medicine.
"I’m convinced that our experience and scientific backgrounds will generate new approaches and increase the potential to create leading products with substantial market potential," Eriksson said.
"However, I would like to emphasize that we’re retaining our focus on pre-eclampsia and renal failure."
A1M Pharma is mainly focused on the development and commercialization of diagnostics and treatment of pre-eclampsia.
NeuroVive develops a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection.